Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

9,951 public trials 2,018 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Active, Not Recruiting

A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)

NCT05673785

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +5 more
Locations
  • Beijing Cancer Hospital Beijing, China
  • Peking University Third Hospital Beijing, China
  • The First Hospital of Jilin University Changchun, China
  • West China Hospital, Sichuan University Chengdu, China
View all 16 locations
View Trial Details
Active, Not Recruiting

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

NCT04484623

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Tucson, Arizona, United States
  • GSK Investigational Site Fort Myers, Florida, United States
  • GSK Investigational Site Boston, Massachusetts, United States
  • GSK Investigational Site Kansas City, Missouri, United States
View all 122 locations
View Trial Details
Active, Not Recruiting

All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

NCT06956170

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Nagoya, Aichi-ken, Japan
  • GSK Investigational Site Kamogawa, Chiba, Japan
  • GSK Investigational Site Kashiwa, Chiba, Japan
  • GSK Investigational Site Matsuyama, Ehime, Japan
View all 13 locations
View Trial Details
Active, Not Recruiting

Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome

NCT04960618

Conditions
Advanced Mycosis Fungoides, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale, New Jersey, United States
  • Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) Commack, New York, United States
View Trial Details
Active, Not Recruiting

Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma

NCT04566887

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • BC Cancer Agency Vancouver, British Columbia, Canada
  • QEII Health Sciences Centre Halifax, Nova Scotia, Canada
  • Princess Margaret Cancer Centre Toronto, Ontario, Canada
  • Sunnybrook Research Institute Toronto, Ontario, Canada
View Trial Details
Active, Not Recruiting

Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

NCT03321643

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +14 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
View Trial Details

Related conditions